European Commission grants marketing authorization for Sandoz’ biosimilar Hyrimoz

By PBR Staff Writer

Novartis division Sandoz has secured marketing authorization from the European Commission (EC) for its biosimilar Hyrimoz (adalimumab) for use in all same indications as reference medicine including rheumatology, gastroenterology and dermatology.